XTL Completes Patient Randomization in Phase IIb Study of Diabetic Pain Drug
Posted on: Tuesday, 1 July 2008, 09:01 CDT
XTL Biopharmaceuticals has completed patient randomization into its Phase IIb study of Bicifadine - a serotonin and norepinephrine reuptake inhibitor - for the treatment of diabetic neuropathic pain.
Approximately 350 patients were randomized into the study. Based on the completion of randomization, the company expects to have the last patient complete the study in the next four months.
The Phase IIb trial is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain, using a study design that is similar to the successful registration trials of Cymbalta, a member of the SNRI class that is approved for this indication, and other approved agents for neuropathic pain.
The Phase IIb study is a randomized, double-blind, placebo-controlled study comparing 200mg 3x/day and 400mg 3x/day of Bicifadine versus placebo, with a 1:1:1 randomization between the three arms, in patients with diabetic neuropathic pain. Approximately 40 clinical centers in the US, Germany, Israel and India are participating in the study.
Following randomization, all patients enter a two-week titration period to allow them to gradually escalate up to their target treatment dose. This is followed by a 12-week steady-state treatment period at the target treatment dose.
The primary endpoint of the study is to compare the efficacy of each of the two active doses of Bicifadine (200mg tid and 400mg tid) versus placebo in reduction of pain associated with diabetic neuropathy, at baseline (at the time of randomization) versus week 14 (week 12 of the steady-state phase).
Source: Datamonitor
Related Articles
- XTL Biopharmaceuticals Completes Phase IIb Diabetic Neuropathic Pain Study
- UCB Receives Not-Approvable Letter From FDA for Lacosamide for Diabetic Neuropathic Pain
- New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
- Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and Was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
- UCB Announces FDA Filing for Lacosamide in the Treatment of Diabetic Neuropathic Pain
- Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
- Avigen Completes Safety, Tolerability and Pharmacokinetic Trial For AV411, a Potential First-in-Class Oral Treatment For Neuropathic Pain; AV411 Phase IIa Study in Australia Continues to Enroll
- Advanced Viral Research Corp. Initiates a Phase I, Safety Study for AVR118 in Type 2 Diabetic Subjects
- AVANIR Initiates Phase III Clinical Trial of Neurodex for the Treatment of Diabetic Neuropathic Pain
- Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes: Early Treatment Diabetic Retinopathy Study Report No. 27
 |
 |
User Comments (0)
RSS Feeds